Company intelligence / Profile preview
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
Shenzhen, Guangdong, Chinabenhealth.cn ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Benhealth’s lead program—anti-CD3/MUC1 bispecific antibody armed cytokine-induced killer cells—is in Phase II clinical trials for late-stage liver cancer in China. The company has presented efficacy and safety data at ASCO and previously initiated but withdrew a trial in gastric cancer prior to enrollment. Other pipeline assets are at preclinical or pending stages.
- Therapeutic areas
- Oncology
- Modalities
- Bispecific antibodiesCell therapies (e.g. cytokine-induced killer cells, CIK)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on Benhealth Biopharmaceutical (Shenzhen) Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Benhealth Biopharmaceutical (Shenzhen) Co., Ltd..